PACT-15

NCT01150630 📎

Regimen

Experimental
Arm B: adjuvant PEXG (cisplatin + epirubicin + capecitabine + gemcitabine) x 6 cycles. Arm C: perioperative PEXG (3 cycles neoadj + 3 cycles adj).
Control
Arm A: adjuvant gemcitabine alone x 6 cycles (standard per CONKO-001).

Population

Resectable PDAC, ECOG 0-1, Italian single-country multicenter (Milan-based), enrolled 2010-2015.

Key finding

PACT-15 signalled that perioperative multi-agent chemotherapy nearly doubles median OS vs adjuvant gemcitabine in resectable PDAC (38.2 vs 20.4 mo). Phase 3 part was halted because the standard of care shifted mid-trial (PRODIGE-24 published), making gemcitabine arm ethically untenable.

Source: PMID 29625841

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.64)